Abstract Activin signals through a heteromeric complex of receptor serine kinases by inducing type II receptor-mediated phosphorylation, and consequent activation, of the type I receptor. Type I receptor phosphorylation occurs at a glycineand serine-rich site in the juxtamembrane domain; phosphorylation at that site correlates with signaling. Investigation of type I activin receptor mutants impaired for GS domain phosphorylation revealed that, in the presence of elevated amounts of type II activin receptor, GS domain phosphorylation is not required for signaling. The type I receptor showed activin-dependent phosphorylation of several tryptic phosphopeptides, suggesting that phosphorylation of receptor I at sites both within and outside the GS domain is required for full signaling.
Introduction
The receptor serine kinase family contains two classes of transmembrane protein serine kinases, the type I receptors and the type II receptors [1] . Members of this family mediate transmembrane signaling for activin, transforming growth factor L (TGFL) and related factors, and are thought to act by formation of a heterooligomeric complex containing both type I and type II receptors. A current model for receptor action posits that ligand binding induces the formation of a type I:type II complex, resulting in type II receptor-mediated activation of the type I receptor by phosphorylation at residues within a conserved glycine-and serine-rich domain in the juxtamembrane region [2] . For activin [3, 4] and TGFL [5] type I receptors (ALK4 and TLRI, respectively), mutation to alanine of the hydroxyamino acids in that GS domain yields molecules which can no longer support ligand-dependent transcriptional activation, implying that such phosphorylation is required for normal signal transduction to occur. The mechanism through which modi¢cation of residues within the GS domain enhances signaling by the type I receptors, either by stimulation of intrinsic enzymatic activity or by recruitment of intracellular signaling molecules, is not currently known.
In an earlier study of the ALK4 GS domain, we observed that potential phosphorylation of some GS domain residues was functionally more signi¢cant than others [3] . Speci¢cally, certain mutants in which four out of ¢ve hydroxyamino acids in the GS domain were changed to alanine retained signi¢cant signaling capacity. In pursuing the correlation of phosphorylation with function, we have now found that under conditions of type II activin receptor (ActR) overexpression, phosphorylation at the GS domain is not absolutely required to generate an activin-dependent transcriptional response.
Materials and methods

Materials
Puri¢ed activin A was generously provided by Dr. Yuzuru Eto, and by the National Hormone and Pituitary Program, the NIDDK, NICHD, and USDA (lot 15365-36). D-Luciferin was obtained from Sigma Chemical Co (St. Louis, MO). [
QP P]Orthophosphate (500 mCi/ ml) was obtained from ICN Pharmaceuticals (Irvine, CA). Activin receptor (ActR) DNAs and p3TP-Lux were as described [3] .
Luciferase assay
The L17 mink lung epithelial cell line [6] was cultured and transfected as described [3] . For luciferase assays, L17 cells were plated at a density of 2.5U10
R cells per well in 24-well plates and grown overnight before transfection. Cells were transfected with 0.5 Wg of the p3TP-Lux reporter plasmid and combinations of ActR DNAs (0.1 Wg) as indicated. Cells were co-transfected with 0.25 Wg of a plasmid expressing L-galactosidase. Following transfection, cells recovered for 30 h and were then stimulated with 2 nM activin A in 0.25 ml medium containing 0.2% fetal bovine serum (v/v). Luciferase activity was measured in 40 Wl of a 200 Wl lysate as described [3] . Luciferase activity was normalized to L-galactosidase activity measured in 20 Wl of lysate as described [7] . The data in Figs. 1^3 show results from single representative experiments; each experiment was repeated at least three times.
Phosphorylation analysis
Cells plated in six-well dishes (approximately 2U10 S cells per well) were transfected with various receptor combinations and allowed to recover in complete medium overnight. The transfected cells were labeled with [
QP P]orthophosphate, and ALK4 proteins were immunoprecipitated with anti-HA antibody [8] exactly as described [3] . Tryptic phosphopeptide mapping and phosphoamino acid analysis were performed exactly as described for ActRII [9, 10] .
Results and discussion
In a previous report [3] we noted that one of three tested quadruple mutants of the ALK4 GS domain (ALK4-4A-S187, in which serine 187 was the only one of the ¢ve serine or threonine residues in the GS domain not mutated) had the capacity to support activin responsiveness in receptor I-de¢-cient cells (see Fig. 1 ). To follow up that observation, all ¢ve quadruple mutants of ALK4 were prepared and tested for their capacity to confer activin inducibility of the 3TP-Lux reporter gene in L17 cells. In addition to ALK4-4A-S187, ALK4-4A-S189 and ALK4-4A-S191 also mediated activin signaling (Fig. 1) . Interestingly, S187, S189 and S191 were the only residues which when mutated in combination of three rendered ALK4 inactive in this assay [3] (see Fig. 2 , ATAAS), consistent with the interpretation that phosphorylation of those speci¢c residues is associated with signaling.
We also showed previously that ALK4-ETEES (S187E, S189E, S191E) had a signaling capacity similar to wild-type. To determine whether that signaling was potentially due to residual phosphorylation of the other residues in the GS domain, we prepared and tested ALK4-EAEEA, which also signaled normally (Fig. 2) . This result supports our earlier conclusion that acidic substitutions of speci¢c hydroxyamino acids in the ALK4 GS domain can mimic functional phosphorylation; however, because basal signaling remained low these data imply that additional activin-dependent regulation of ALK4 is required for full activity (see below).
Because L17 cells express very low amounts of type II ActRs as judged by ligand binding experiments (not shown), we determined the e¡ect of overexpression of ActRIIB together with di¡erent GS domain mutants. Fig. 3 shows representative results for a partially active quadruple mutant (4A-S189), an inactive quadruple mutant (4A-S193), and the non-phosphorylatable mutant ALK4-5A. Surprisingly, expression of elevated amounts of ActRIIB increased the activin responsiveness conferred on the cells by all the ALK4 mutants tested, including ALK4-5A. For 4A-S189, the change in activin induction was increased from 3^5 fold in the absence of ActRIIB to 10^20 fold in the presence of ActRIIB; for 4A-S193 and 5A, the corresponding induction went from approximately 1.5 fold to 3^8 fold. As previously observed, overexpression of ActRIIB alone neither a¡ected basal expression of the reporter gene nor rendered the cells responsive to activin. Both ActRII and ActRIIB had this ALK4-potentiating activity, while TLRII did not (not shown). The kinase activity of ActRIIB was essential to bring about this rescue of ALK4 signaling, as an enzymatically inactive mutant (ActRIIB-K217R) was unable to induce an activin response (Fig. 3) .
It is possible that GS domain phosphorylation markedly increases ALK4 activity, but that ALK4 mutants which are not phosphorylated at the GS domain do have very low basal signaling activity when complexed with type II receptors. Because receptor II is present only at very low amounts in L17 cells, that low amount of signaling is insu¤cient to generate a biological response from ALK4-5A. Quantitatively increasing the number of receptor complexes formed^by overexpression of ActRIIB^could thus lead to enough of an increase in the number of weakly signaling ALK4-5A:ActRIIB complexes to allow for a modest response to activin treatment. Given that type II receptor kinase activity was required for this response, the enhanced ALK4 activity is likely due to increased phosphorylation at a site(s) distinct from the GS domain.
To examine ALK4 phosphorylation, ALK4 and ALK4-5A were transiently expressed in L17 cells together with ActRIIB, metabolically labeled with [
QP P]orthophosphate, and analyzed WT, wild-type GS domain sequence (STSGSGS, S187, T188, S189, S191, S193). Cells were treated with activin and assayed as in Fig. 1 . Fig. 3 . E¡ect of type II activin receptor on type I receptor signaling. L17 cells were transfected with 3TP-Lux together with combinations of di¡erent type I and type II receptor constructs as indicated. Cells were treated with activin and assayed as in Fig. 1 . WT, wild-type ActRIIB; KR, ActRIIB-K217R, an enzymatically inactive point mutant.
by immunoprecipitation. Although both proteins were expressed in comparable amounts (not shown), ALK4 was phosphorylated to a substantially greater extent than was ALK4-5A in both the basal and ligand-activated states (Fig.  4A) . The reduced phosphorylation observed in ALK4-5A is consistent with the wild-type receptor undergoing modi¢ca-tion at the GS domain. Phosphoamino acid analysis of those samples revealed that ALK4 was phosphorylated primarily on serine, with a minor component on threonine; phosphotyrosine was not detected (Fig. 4B) . Phosphothreonine was not detected in ALK4-5A, suggesting that T188 in the GS domain is phosphorylated in the wild-type protein; curiously, T188 is not one of the residues implicated by the mutagenic analysis as required for signaling. As previously observed [3] , activin treatment resulted in a modest increase in ALK4 phosphorylation; an increase in phosphorylation of ALK4-5A was also seen (Fig. 4A) .
To visualize those phosphorylation sites, QP P-labeled proteins were digested with trypsin and resolved in two dimensions on thin-layer chromatography plates. For wild-type ALK4, a number of novel tryptic phosphopeptides were detected in the activin-treated sample that were not present in the basal state (Fig. 4C) . Although the identities of those various peptides are not currently known, it is likely that some of them represent phosphorylation at the GS domain and some represent phosphorylation of other sites. The GS domain is contained on a single tryptic phosphopeptide; however, di¡erent phosphoisomers would have di¡erent mobilities under these conditions. Given the reduced amount of phosphorylation of ALK4-5A, clear tryptic phosphopeptide maps have not been generated for that receptor; however, the increase in overall phosphorylation in response to activin treatment is consistent with the interpretation that ligand-regulated phosphorylation occurs at non-GS domain sites.
Taken together, the following observations support the notion that phosphorylation of activin type I receptor must occur at both the GS domain and additional residues to achieve full activation.
(1) ALK4-5A, which cannot be phosphorylated at the GS domain, can support activin signaling in the presence of a su¤cient amount of type II receptor. (2) Acidic substitution of key residues in the GS domain can apparently mimic phosphorylation at those sites, but is insu¤cient to generate a constitutively active receptor. (3) Analysis of ALK4 and ALK4-5A phosphorylation indicates the presence of several activin-inducible sites of phosphorylation. It has been suggested that phosphorylation of residues in the juxtamembrane domain of TLRI a¡ects TGFL signaling [11, 12] . Mutation of the cognate residues in ALK4 (S168 and S174) to alanine had no e¡ect on ALK4 activity (not shown). Identi¢cation of the other sites of ALK4 phosphorylation and determination of their functional signi¢cance are under way.
